Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Precision Radiation for OligoMetastatIc and MetaStatic DiseasE (PROMISE)-004: Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression

NCT03808662 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT03808662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03808662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Precision Radiation for OligoMetastatIc and MetaStatic DiseasE (PROMISE)-004: Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 16, 2019
Completion date
January 31, 2027
Enrollment
107 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer, non small cell lung cancer metastatic, nsclc, nsclc stage iv, nsclc stage iv without egfr/alk mutation, tnbc - triple-negative breast cancer, triple negative breast cancer